Biosimilar insulins: An unavoidable option in South-East Asia

The Future of Biosimilar Insulins

IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a biosimilar product and its reference insulin, the ramifications of having the same name or different names for a biosimilar and its reference insulin, ...

Biosimilar insulins: a European perspective

Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes th...

Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review.

BACKGROUND Multiple sclerosis (MS) is one of the most common chronic immune-mediated diseases of the human central nervous system and an important cause of non-traumatic neurologic disability among young population in several countries. Recent reports from East Asia, South East Asia and South Asia have proposed a low to moderate prevalence of MS in these countries. METHODS A literature review...

Influenza in South-East Asia.

period through subclinical or mild infection occurring sporadically. In order to understand how the virus infection recurs in the temperate epidemic zone, a hypothesis has been presented by Fukumi3 that the virus may survive through infections occurring sporadically in the tropical virus-reservoir zone. Several virological and epidemiological studies have been published on influenza in Thailand...

Psychiatry in South-East Asia.